Nutrition 21 Inc. said Wednesday that it agreed to the Food and Drug Administration’s request for a 60-day extension to review qualified health claims for chromium picolinate, pushing the agency’s decision date to June 17. Nutrition 21 shares fell 11 cents, or 9.2 percent, to $1.08 in afternoon trading on the Nasdaq. Chromium picolinate is one of the ingredients of the company’s Diachrome nutritional supplement. Additionally, the maker of nutritional products said it will present promising data on Diachrome for the treatment of Type 2 diabetes this spring. The company said that data from a 453-patient will show that the supplement is safe and beneficial for patients with Type 2 diabetes and related conditions.
